Further insights about the beneficial effects of n-3 fatty acids in the early molecular events of renal fibrosis in vitro

Journal of Nephrology

Volumn 26, Issue 4, 2013, Pages 652-659

  Priante, Giovanna ^a   Musacchio, Estella ^a   Valvason, Chiara ^a   Clari, Giulio ^a   Bordin, Luciana ^a   Sartori, Leonardo ^a   Baggio, Bruno ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

DHA; EPA; Mesangial cells; Renal fibrosis

Indexed keywords

ANGIOTENSIN II; CYCLOOXYGENASE 2; DECORIN; DOCOSAHEXAENOIC ACID; FIBROBLAST GROWTH FACTOR; GELATINASE A; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLATELET DERIVED GROWTH FACTOR; PROTEIN BAX;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; KIDNEY FIBROSIS; MOLECULAR MECHANICS; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

CELLS, CULTURED; FATTY ACIDS, OMEGA-3; FIBROSIS; HUMANS; KIDNEY;

EID: 84880083485     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000193     Document Type: Article

References (40)

1. Donadio JV Jr, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC; Mayo Nephrology Collaborative Group. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. J Am Soc Nephrol. 1999;10(8):1772-1777.
2. Garman JH, Mulroney S, Manigrasso M, Flynn E, Maric C. Omega-3 fatty acid rich diet prevents diabetic renal disease. Am J Physiol Renal Physiol. 2009;296(2):F306-F316.
3. Fassett RG, Gobe GC, Peake JM, Coombes JS. Omega-3 polyunsaturated fatty acids in the treatment of kidney disease. Am J Kidney Dis. 2010;56(4):728-742.
4. Gopinath B, Harris DC, Flood VM, Burlutsky G, Mitchell P. Consumption of long-chain n-3 PUFA, α-linolenic acid and fish is associated with the prevalence of chronic kidney disease. Br J Nutr. 2011;105(9):1361-1368.
5. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83(6) (Suppl):1505S-1519S.
6. Baggio B. Fatty acids, calcium and bone metabolism. J Nephrol. 2002;15(6):601-604.
7. Priante G, Musacchio E, Valvason C, Baggio B. EPA and DHA suppress AngII-and arachidonic acid-induced expression of profibrotic genes in human mesangial cells. J Nephrol. 2009;22(1):137-143.
8. Lenz O, Elliot SJ, Stetler-Stevenson WG. Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol. 2000;11(3):574-581.
9. Thrailkill KM, Clay Bunn R, Fowlkes JL. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine. 2009;35(1):1-10.
10. Border WA, Noble NA, Yamamoto T, et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature. 1992;360(6402): 361-364.
11. Costacurta A, Priante G, D'Angelo A, Chieco-Bianchi L, Cantaro S. Decorin transfection in human mesangial cells downregulates genes playing a role in the progression of fibrosis. J Clin Lab Anal. 2002;16(4):178-186.
12. Floege J, Eng E, Young BA, et al. Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J Clin Invest. 1993;92(6):2952-2962.
13. Fujita Y, Maruyama S, Kogo H, Matsuo S, Fujimoto T. Caveolin-1 in mesangial cells suppresses MAP kinase activation and cell proliferation induced by bFGF and PDGF. Kidney Int. 2004;66(5):1794-1804.
14. Rotstein NP, Politi LE, German OL, Girotti R. Protective effect of docosahexaenoic acid on oxidative stress-induced apoptosis of retina photoreceptors. Invest Ophthalmol Vis Sci. 2003;44(5):2252-2259.
15. Chiu LC, Wong EY, Ooi VE. Docosahexaenoic acid from a cultured microalga inhibits cell growth and induces apoptosis by upregulating Bax/Bcl-2 ratio in human breast carcinoma MCF-7 cells. Ann N Y Acad Sci. 2004;1030(1):361-368.
16. Alique M, Calleros L, Luengo A, et al. Changes in extracellular matrix composition regulate cyclooxygenase-2 expression in human mesangial cells. Am J Physiol Cell Physiol. 2011;300(4):C907-C918.
17. Yoshihara D, Kurahashi H, Morita M, et al. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol. 2011;300(2):F465-F474.
18. Kawai T, Masaki T, Doi S, et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest. 2009;89(1):47-58.
19. Priante G, Bordin L, Musacchio E, Clari G, Baggio B. Fatty acids and cytokine mRNA expression in human osteoblastic cells: a specific effect of arachidonic acid. Clin Sci (Lond). 2002;102(4):403-409.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(1):156-159.
21. Schroeder A, Mueller O, Stocker S, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol. 2006;7(1):3.
22. Musacchio E, Priante G, Budakovic A, Baggio B. Effects of unsaturated free fatty acids on adhesion and on gene expression of extracellular matrix macromolecules in human osteoblastlike cell cultures. Connect Tissue Res. 2007;48(1):34-38.
23. Oliver MH, Harrison NK, Bishop JE, Cole PJ, Laurent GJ. A rapid and convenient assay for counting cells cultured in microwell plates: application for assessment of growth factors. J Cell Sci. 1989;92(Pt 3):513-518.
24. Baggio B, Musacchio E, Priante G. Polyunsaturated fatty acids and renal fibrosis: pathophysiologic link and potential clinical implications. J Nephrol. 2005;18(4):362-367.
25. Ruiz-Ortega M, Rupérez M, Esteban V, et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant. 2006;21(1):16-20.
26. Rüster C, Wolf G. Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J Am Soc Nephrol. 2011;22(7): 1189-1199.
27. Matrisian L. Metalloproteinases and their inhibitors in matrix remodelling. Trends Genet. 1996;6:121-125.
28. Kato H, Osajima A, Uezono Y, et al. Involvement of PDGF in pressure-induced mesangial cell proliferation through PKC and tyrosine kinase pathways. Am J Physiol. 1999;277(1 Pt 2): F105-F112.
29. Ostendorf T, Eitner F, Floege J. The PDGF family in renal fibrosis. Pediatr Nephrol. 2011.
30. Floege J, Burns MW, Alpers CE, et al. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int. 1992;41(2):297-309.
31. Johnson RJ, Floege J, Couser WG, Alpers CE. Role of platelet-derived growth factor in glomerular disease. J Am Soc Nephrol. 1993;4(2):119-128.
32. Giros A, Grzybowski M, Sohn VR, et al. Regulation of colorectal cancer cell apoptosis by the n-3 polyunsaturated fatty acids Docosahexaenoic and Eicosapentaenoic. Cancer Prev Res (Phila). 2009;2(8):732-742.
33. Davies M, Kastner S, Thomas GJ. Proteoglycans: their possible role in renal fibrosis. Kidney Int Suppl. 1996;54:S55-S60.
34. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature. 1990;346(6281):281-284.
35. Sheu ML, Chao KF, Sung YJ, Lin WW, Lin-Shiau SY, Liu SH. Activation of phosphoinositide 3-kinase in response to inflammation and nitric oxide leads to the up-regulation of cyclooxygenase-2 expression and subsequent cell proliferation in mesangial cells. Cell Signal. 2005;17(8):975-984.
36. Jaimes EA, Hua P, Tian RX, Raij L. Human glomerular endothelium: interplay among glucose, free fatty acids, angiotensin II, and oxidative stress. Am J Physiol Renal Physiol. 2010;298(1):F125-F132.
37. Camilla R, Suzuki H, Daprà V, et al. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol. 2011;6(8):1903-1911.
38. Li H, Ruan XZ, Powis SH, et al. EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism. Kidney Int. 2005;67(3):867-874.
39. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391(6662):79-82.
40. Inoue H, Tanabe T, Umesono K. Feedback control of cyclooxygenase-2 expression through PPARgamma. J Biol Chem. 2000;275(36):28028-28032.